1. What Is the Subdermal Implant Market?
The Subdermal Implant Market encompasses thin rod-shaped or pellet-form devices inserted beneath the skin, primarily in the upper arm or buttock. They provide long-acting contraceptive hormone delivery or biometric data monitoring from a discreet body-worn implanted platform. The market includes single-rod etonogestrel contraceptive implants, two-rod levonorgestrel implant systems, biodegradable contraceptive implants, subcutaneous hormone pellets for hormone replacement therapy, and near-field communication chip identification and biometric implants. These devices are inserted through a small skin puncture using a trocar applicator by healthcare providers in clinic settings. They provide three to five years of hormone delivery without daily patient compliance, or biometric data available without external device interaction. Market scope covers rod-shaped and pellet subdermal implant products for hormone delivery and biometric monitoring, and excludes injectable depot contraceptive formulations, implantable cardioverter defibrillators and cardiac monitors, and surgically implanted port systems for intravenous access.
2. Subdermal Implant Market Size & Forecast
3. Emerging Technologies
- Biodegradable progestin contraceptive implant development is advancing PLGA and polycaprolactone polymer rod formulations that provide three-year contraceptive progestin release before dissolving without requiring implant removal, addressing the primary patient barrier of the. Growing contraceptive.
- Near-field communication subdermal implant technology is advancing biocompatible NFC transponder chips encapsulated in medical-grade glass or biopolymer for subcutaneous implantation that enable contactless identification, digital key access, and health data display. Growing industry adoption of this technology is motivating development.
- Continuous glucose monitoring subdermal implant integration is advancing long-duration subcutaneous glucose sensor designs that incorporate etonogestrel contraceptive function into a dual-purpose subdermal implant providing both contraception and CGM glucose monitoring. Growing industry adoption of this technology is motivating development.
- Implant-integrated drug delivery platform development is advancing subdermal implant architectures incorporating drug-loaded polymer matrices within the implant body alongside contraceptive progestin, enabling co-delivery of HIV pre-exposure prophylaxis or antimalarial drugs alongside contraceptive hormone for. Growing industry adoption of this technology is motivating development.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Retinal Implant Market.
4. Key Market Opportunity
One of the key opportunities in the Subdermal Implant Market is the expansion of contraceptive implant uptake among adolescent and young adult women through post-partum and post-abortion LARC insertion programmes that provide the highest contraceptive continuation rates at the most clinically appropriate insertion timing. A significant proportion of post-partum and post-abortion women with high unintended pregnancy risk decline long-acting reversible contraception follow-up insertion at a separate appointment, while same-appointment post-partum and post-abortion Nexplanon insertion achieves substantially higher LARC adoption and continuation. Post-partum Nexplanon insertion before hospital discharge eliminates the follow-up appointment attendance barrier, providing the highest-efficacy contraception at the moment of highest motivation for preventing unintended pregnancy. Contraceptive implant manufacturers that provide post-partum LARC programme implementation toolkits, train maternity hospital staff in subdermal implant insertion, and support hospital formulary procurement of Nexplanon for immediate post-partum insertion are positioned to capture this high-value LARC adoption opportunity.
5. Top Companies in the Subdermal Implant Market
The following organisations hold leading positions in the Subdermal Implant Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Organon (Nexplanon)
- Bayer (Jadelle)
- Shanghai Dahua (Sino-Implant II)
- BioTE Medical
- SottoPelle
- VivoSense
- Dangerous Things
- Chip Chick
- Nuffield Health
- Population Services International
6. Market Segmentation
The Subdermal Implant Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Product Type | Etonogestrel Contraceptive Implant Nexplanon Single Rod Implanon NXT Levonorgestrel Contraceptive Implant Jadelle Two-Rod System Sino-Implant II Biodegradable Contraceptive Implant Investigational Biodegradable Rod Hormone Pellet Implant Testosterone Pellet Oestradiol Pellet Biometric Implant NFC Identification Chip Biometric Health Monitor |
| By Hormone | Progestin Implant Etonogestrel Implant Levonorgestrel Implant Oestrogen Implant Oestradiol Subcutaneous Testosterone Implant Testosterone Pellet HRT Combined Hormone Investigational Combined Implant |
| By Indication | Contraception Long-Acting Reversible Contraception Post-Partum Contraception Hormone Replacement Therapy Female HRT Subdermal Male Testosterone Replacement Biometric Identification NFC Implant ID Health Monitoring Subdermal Sensor Implant |
| By End User | Gynaecology and Family Planning Clinics Contraceptive Implant Clinic Primary Care GP Contraceptive Implant Hospital Obstetrics Post-Partum LARC Placement Wellness and Anti-Ageing Clinics Hormone Pellet Clinic Biohacker Clinics NFC Implant Sites |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Subdermal Implant Market trajectory over the forecast period:
Nexplanon Etonogestrel Implant Technology Is Maintaining Its Position as the Highest-Efficacy Long-Acting Reversible Contraceptive Available.Gynaecologists, family planning clinicians, and primary care providers counselling patients on contraception are recommending Nexplanon as the most effective reversible contraceptive with a Pearl Index below 0_1 per 100 woman-years. Additionally outperforming oral contraceptive pills, IUDs, all barrier methods on contraceptive efficacy. Organon continued commercial development and international market access expansion of Nexplanon etonogestrel contraceptive implant in 2024, with growing family planning programme adoption in low and middle-income countries through donor-funded LARC access initiatives.
Jadelle Levonorgestrel Two-Rod Implant Technology Is Providing Affordable Long-Acting Contraception in Low-Income Country Family Planning Programmes.Global health funding organisations and government family planning programmes in sub-Saharan Africa and Southeast Asia are procuring Jadelle two-rod levonorgestrel implants as a cost-effective five-year LARC option for women without access to Nexplanon-level healthcare infrastructure. Bayer continued commercial and donor supply chain development of Jadelle levonorgestrel contraceptive implants for government. NGO family planning programme procurement in 2024, maintaining Jadelle's position as the primary lower-cost contraceptive implant in global health LARC access programmes.
Subcutaneous Hormone Pellet Technology Is Expanding Testosterone and Oestradiol Replacement Therapy Beyond Conventional Injections and Transdermal Patches.Anti-ageing and wellness medicine clinicians and endocrinologists managing patients with hypogonadism and menopause are implanting subcutaneous testosterone. Oestradiol pellets that provide consistent hormone delivery for three to six months without the daily transdermal patch application or weekly injection administration required by conventional hormone replacement routes. BioTE Medical and SottoPelle continued commercial expansion of subcutaneous hormone pellet insertion training programmes for healthcare providers. Direct patient marketing of pellet HRT as an alternative to conventional hormone replacement routes in 2024, growing wellness clinic and anti-ageing medicine adoption of pellet insertion as a clinic revenue service.
For related market intelligence, see the Cortical Implant Market.
8. Segmental Analysis
By product type, etonogestrel contraceptive implants dominated the Subdermal Implant Market in 2025, driven by Nexplanon's position as the most prescribed single-rod LARC globally and its comprehensive insurance coverage and clinical evidence base. Gynaecologists and family planning clinicians continue specifying Nexplanon etonogestrel implant as the primary long-acting reversible contraceptive recommendation as its efficacy, three-year duration, and reversibility make it the preferred LARC option. Hormone pellet implants are the fastest-growing product type, driven by growing wellness clinic and anti-ageing medicine adoption of subcutaneous testosterone and oestradiol pellet insertion as a long-acting hormone replacement alternative. Anti-ageing medicine clinicians and endocrinologists are increasing hormone pellet insertion as patients seek consistent hormone delivery over three to six months without the compliance requirements of conventional hormone replacement administration.
By indication, contraception dominated the Subdermal Implant Market in 2025, driven by the large global long-acting reversible contraception market and Nexplanon's dominant position across high-income and global health markets. Gynaecologists, family planning clinics, and global health programme providers continue generating the highest subdermal implant demand as contraceptive implant insertion is the primary clinical indication driving etonogestrel and levonorgestrel rod implant procurement. Hormone replacement therapy is the fastest-growing indication, driven by growing wellness clinic adoption of subcutaneous pellet HRT for testosterone deficiency and menopause management as an alternative to conventional daily and weekly replacement modalities. Wellness medicine providers and endocrinologists are increasing subcutaneous hormone pellet adoption as evidence demonstrates stable hormone levels from pellet delivery versus the hormone level fluctuation associated with injectable and transdermal conventional HRT administration.
9. Regional Analysis
Regional demand patterns across the Subdermal Implant Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Subdermal Implant Market in 2025, holding 35.0% of the global market. The region's dominance reflects the established United States market for Nexplanon etonogestrel contraceptive implant under comprehensive private and Medicaid contraceptive coverage, the growing subcutaneous hormone pellet wellness clinic market, and the concentration of contraceptive implant manufacturers with North American commercial headquarters. Growing United States Title X family planning programme Nexplanon procurement and expanding Medicaid LARC coverage for post-partum contraceptive implant insertion are creating consistent demand for etonogestrel implants at public health family planning and hospital obstetrics programmes. The growing United States wellness medicine and anti-ageing clinic market for subcutaneous testosterone and oestradiol hormone pellet insertion is expanding the subdermal implant market beyond traditional contraceptive implant revenues to include hormone replacement therapy pellet products.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 12.00% during the forecast period. Growing government family planning programme investment, expanding LARC access initiatives endorseed by global health funding, and increasing contraceptive implant adoption in Indonesia, the Philippines, Bangladesh, India, and China are creating demand for etonogestrel and levonorgestrel contraceptive subdermal implants. Indonesian and Philippine government family planning programmes have established large-scale Jadelle and Nexplanon procurement through global health donor partnerships, generating significant contraceptive implant volume demand at public health family planning service delivery points. Growing Indian government family planning scheme investment in long-acting reversible contraception and expanding LARC training for community health workers are increasing contraceptive implant insertion capacity and adoption at rural and urban family planning centres.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Subdermal Implant Market was valued at USD 916.91 Mn in 2025 and is projected to reach USD 1,910.69 Mn by 2034, growing at a CAGR of 8.50% over the 2026–2034 forecast period.
The Subdermal Implant Market is projected to grow at a CAGR of 8.50% from 2026 to 2034.
North America accounted for the largest share of the Subdermal Implant Market in 2025, holding 35.0% of the global market.
The leading companies in the Subdermal Implant Market include Organon (Nexplanon), Bayer (Jadelle), Shanghai Dahua (Sino-Implant II), BioTE Medical, SottoPelle, VivoSense, Dangerous Things, Chip Chick, Nuffield Health, Population Services International.
Nexplanon etonogestrel implant technology is maintaining its position as the highest-efficacy long-acting reversible contraceptive available.
By product type, etonogestrel contraceptive implants dominated the Subdermal Implant Market in 2025, driven by Nexplanon's position as the most prescribed single-rod LARC globally and its comprehensive insurance coverage and clinical evidence base.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.